Clinical trials: Dermatologic Diseases
Alopecia
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.
- Trial name
- NCT03594227
- Testing
- ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose)
- Where
- 25 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Aclaris Therapeutics, Inc.
Psoriasis
Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)
This is a long-term, randomized, multi-center, open-label study of infliximab treatment in adults with moderate to severe plaque-type psoriasis.
- Trial name
- NCT00358670
- Testing
- infliximab
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
Hidradenitis Suppurativa
Etanercept for Treatment of Hidradenitis
This study is being done to test a drug called etanercept (Enbrel®). Etanercept has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate to severe plaque psoriasis (PsO), for use in…
- Trial name
- NCT00107991
- Testing
- etanercept
- Volunteers
- 15 people
- Sponsor
- University of Pennsylvania
Breast Cancer, Cancer of Breast
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast…
- Conditions
- Breast Cancer, Cancer of Breast, Breast Carcinoma
- Trial name
- PALTAN (NCT02907918)
- Testing
- Palbociclib, Letrozole, Trastuzumab
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
- Trial name
- OlympiA (NCT02032823)
- Testing
- Olaparib
- Where
- 698 sites in United States, Argentina and 22 more
- Volunteers
- 1,837 people
- Sponsor
- AstraZeneca
Acne Vulgaris
Afamelanotide in Patients Suffering With Acne Vulgaris
This study aims to evaluate the effect of afamelanotide on the facial inflammatory acne-related lesions in patients with mild to moderate acne vulgaris, including tolerability of afamelanotide by patients with moderate acne…
- Trial name
- NCT04943159
- Testing
- Afamelanotide
- Volunteers
- 3 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Disorder of Nipple, Breast Neoplasms
Diagnostic Utility of MRI in Female Patients With Nipple Discharge: A Prospective Trial
The purpose of the proposed prospective study is to determine the diagnostic value of MRI for the evaluation of patients with pathologic nipple discharge.
- Trial name
- NCT02818946
- Testing
- MRI
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Duke University
HER2 Negative Metastatic Breast Cancer
Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer
90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly Paclitaxel to determine the difference in progression…
- Trial name
- CONCEPT (NCT03048942)
- Testing
- Cabazitaxel, Paclitaxel
- Where
- 13 sites in United Kingdom
- Volunteers
- 158 people
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
Breast Carcinoma
Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
This clinical trial studies the use of contrast-enhanced ultrasound (CEUS) in estimating tissue pressure in patients with breast cancer. Diagnostic procedures, such as CEUS, may help estimate tissue pressure noninvasively.
- Trial name
- NCT04721886
- Testing
- Ultrasonsgraphy, Perflutren Lipid Microcpheres, Contrast - Enhanced Ultrasound
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Thomas Jefferson University
Breast Cancer
Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
The purpose of this study is to determine whether denosumab compared to placebo, will reduce the rate of first clinical fracture in women with non-metastatic breast cancer receiving (non-steroidal) aromatase inhibitor therapy.
- Trial name
- NCT00556374
- Testing
- Denosumab, Non-steroidal aromatase inhibitor therapy, Zoledronic Acid
- Where
- 46 sites in Austria, Sweden
- Volunteers
- 3,420 people
- Sponsor
- Amgen
Atopic Dermatitis, Eczema
Steroid-reducing Effects of Crisaborole
Atopic dermatitis, or eczema, is a chronic skin condition affecting many children. Crisaborole is a non-steroid topical medication which is FDA approved for children aged 2 and older for eczema.
- Trial name
- NCT03832010
- Testing
- Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alopecia, Androgenetic
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
- Trial name
- NCT05802173
- Testing
- TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Technoderma Medicines Inc.
Dermatomyositis
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants…
- Trial name
- NCT04999020
- Testing
- Ravulizumab
- Where
- 111 sites in United States, Australia and 11 more
- Volunteers
- 38 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Acne Vulgaris
Weekly Isotretinoin Therapy Study
In current Dermatology practice, options for moderate acne vulgaris remain limited. The mainstay of treatment for moderate acne remains long courses of oral antibiotics despite emerging antibiotic resistance.
- Trial name
- WIT (NCT04594759)
- Testing
- Isotretinoin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Medical University of South Carolina
Breast Cancer
Cook for Your Life!: Implementing Dietary Change Among Hispanic Breast Cancer Survivors
The primary objectives of this study are to determine the effect of the dietary intervention (Cocinar para su salud! Program) vs.
- Trial name
- NCT01414062
- Testing
- Cocinar Para Su Salud Program, Written dietary recommendations
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Columbia University
Advanced Melanoma
Phase II FANG™ in Advanced Melanoma
Preliminary studies with a variety of vaccines suggest target accessibility (potential immunogenicity) in a variety of solid tumors to immune directed approaches.
- Trial name
- NCT01453361
- Testing
- Vigil™ Vaccine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gradalis, Inc.
Psoriasis
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to clobetasol propionate cream, 0.05% cream when applied twice daily for 15 days.
- Trial name
- HPA axis (NCT02131324)
- Testing
- DFD06 Cream, Clobetasol Propionate Cream 0.05%
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Promius Pharma, LLC
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
- Trial name
- NCT01446159
- Testing
- MEDI-573, Aromatase Inhibitor
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 188 people
- Sponsor
- MedImmune LLC
Psoriasis
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of guselkumab on coronary flow reserve (CFR), measured by transthoracic doppler-echocardiography, in participants with moderate-to-severe psoriasis and intermediate…
- Trial name
- G-CARE (NCT05125679)
- Testing
- Guselkumab
- Where
- 5 sites in Germany, Greece and 1 more
- Volunteers
- 15 people
- Sponsor
- Janssen-Cilag Ltd.
Hearing Loss, Sensorineural, Hearing Loss, Conductive
Wide Frequency Band Test of Hearing in Veterans
The accurate assessment of auditory status is critical for planning treatment for Veterans with hearing loss to include medical and audiological management.
- Conditions
- Hearing Loss, Sensorineural, Hearing Loss, Conductive, Hearing Loss, Mixed Conductive-Sensorineural, Otosclerosis
- Trial name
- CWTBAFV (NCT02019888)
- Where
- 2 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.